Figures computed from official regulatory filings — .
Analysttarget 9 USD (+6%) · consensus 4.29/5 · 5 buy · 2 hold · 0 sell
Ownershipinsiders 20.06% · institutions 52.42% · short 3.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Sight Sciences, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
44 buys89 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Rodberg James | Sell | $63.8K | SEC |
| Badawi David | Sell | $70.6K | SEC |
| Taylor Brenton | Sell | $26.5K | SEC |
| Badawi Paul | Sell | $268.3K | SEC |
| Bauerlein Alison | Sell | $223.6K | SEC |
| Rashid Kashif | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rodberg James | Sell | $37K | SEC |
| Taylor Brenton | Sell | $15.3K | SEC |
| HAYDEN JEREMY B. | Sell | $70.1K | SEC |
| Badawi Paul | Sell | $155.5K | SEC |
| Badawi David | Sell | $40.9K | Unusual size | SEC |
| Bauerlein Alison | Sell | $129.6K | SEC |
| Encrantz Staffantrack record | Buy | $68.8K | conv 18 | SEC |
| Mazzacco Catherine | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zurbay Donald | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Encrantz Staffantrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Burbach Gerhard F | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fountain Tamara | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bauerlein Alison | Sell | $65.2K | SEC |
| HAYDEN JEREMY B. | Sell | $48.9K | SEC |
| Rodberg James | Sell | $25.7K | SEC |
| Taylor Brenton | Sell | $10.6K | SEC |
| Badawi Paul | Sell | $108.2K | SEC |
| Badawi David | Sell | $28.4K | SEC |
| Bauerlein Alison | Sell | $90K | SEC |